Bluebird’s Fast Lyfgenia Launch Was A Year And A Half In The Making; Medicaid Talks Continuing
Zynteglo Build Gives Firm A Leg Up In Sickle Cell Disease
When Zynteglo was approved for beta-thalassemia, bluebird said launch would lay groundwork for sickle cell gene therapy Lyfgenia. The strategy is paying off so far with a fast ramp-up. Outcomes-based contracts for Lyfgenia give payers rebate based on hospitalizations over a three-year period.
